SeaStar Medical Reports 82% Revenue Growth but Faces Increased Losses in Q2 2026

SeaStar Medical Holding Corporation reported its financial results for the second quarter of 2026, revealing a net revenue of $615,000 for the three months ended June 30, 2026, an increase of 82% compared to $338,000 for the same period in 2025. For the first half of 2026, the company generated $1.11 million in revenue, up from $631,000 in the prior year. Despite this growth, SeaStar recorded a net loss of $3.73 million for the second quarter, compared to a loss of $2.00 million in the same quarter of 2025. The company’s accumulated deficit increased to $159 million as of June 30, 2026, from $151.7 million at the end of 2025.

The increase in revenue is attributed to heightened customer adoption of SeaStar's QUELIMMUNE therapy, which is the only FDA-approved treatment for pediatric patients with acute kidney injury due to sepsis. The company has been actively working on expanding its customer base and enhancing demand for its product. However, operating expenses surged to $4.35 million in the second quarter, up from $2.07 million in the same period last year, primarily driven by increased research and development costs associated with ongoing clinical trials and general administrative expenses.

Operationally, SeaStar Medical has made significant strides in its clinical development efforts. The company is currently conducting a pivotal trial, NEUTRALIZE-AKI, to evaluate the safety and efficacy of its Selective Cytopheretic Device (SCD) therapy in adult patients with acute kidney injury. The company has also received multiple Breakthrough Device Designations from the FDA, which are expected to expedite the regulatory approval process for various indications. As of June 30, 2026, SeaStar employed 18 individuals, a slight increase from 17 employees at the end of 2025.

Despite the positive developments, SeaStar faces challenges regarding its liquidity and ability to continue operations. The company reported cash reserves of $6.96 million as of June 30, 2026, down from $11.98 million at the end of 2025. Management has expressed concerns about the company's ability to fund its operations for the next 12 months without additional capital. The company plans to seek further financing through equity or debt securities, collaborations, or grants, but acknowledges that there is no assurance that such funding will be available on acceptable terms.

Looking ahead, SeaStar Medical aims to continue its focus on the commercialization of QUELIMMUNE while advancing its adult SCD therapy through clinical trials. The company anticipates that its revenue will fluctuate as it introduces QUELIMMUNE to pediatric hospitals and works towards obtaining regulatory approval for its adult SCD. The management's outlook remains cautious, emphasizing the need for additional capital to support ongoing operations and development activities.